RENOVARO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.7 USD | -13.71% |
|
-26.09% | -46.37% |
| Apr. 24 | Renovaro's RenovaroCube Amends Agreement to Acquire 100% Stake in Cyclomics | MT |
| Apr. 18 | Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board | CI |
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 34.41M |
|---|---|---|---|---|---|
| Net income 2022 | -113M | Net income 2023 | -39M | EV / Sales 2022 | - |
| Net cash position 2022 | 1.99M | Net Debt 2023 | 3.9M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.89
x | P/E ratio 2023 |
-0.8
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.77% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -13.71% | ||
| 1 week | -26.09% | ||
| Current month | -35.85% | ||
| 1 month | -41.58% | ||
| 3 months | -65.13% | ||
| 6 months | -41.18% | ||
| Current year | -46.37% |
1 week
1.56
2.20
1 month
1.563.05
Current year
1.565.25
1 year
0.395.25
3 years
0.3913.78
5 years
0.3913.78
10 years
0.3913.78
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Dybul
CEO | Chief Executive Officer | 60 | 18-01-22 |
Lester Russell
CTO | Chief Tech/Sci/R&D Officer | - | 23-08-20 |
Greg Duczynski
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Alton
BRD | Director/Board Member | 58 | 19-12-31 |
Avram Miller
BRD | Director/Board Member | - | 23-10-10 |
James Sapirstein
BRD | Director/Board Member | 62 | 18-03-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 18 M€ | +3.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 1.7 | -13.71% | 427,977 |
| 24-04-24 | 1.97 | -2.48% | 206,935 |
| 24-04-23 | 2.02 | -6.05% | 292,628 |
| 24-04-22 | 2.15 | -0.92% | 110,931 |
| 24-04-19 | 2.17 | -5.65% | 207,913 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.
| 1st Jan change | Capi. | |
|---|---|---|
| -46.37% | 283M | |
| -2.26% | 104B | |
| +1.41% | 97.42B | |
| +0.79% | 22.2B | |
| -17.84% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.63% | 15.06B | |
| +4.55% | 13.98B | |
| +32.11% | 11.66B |
- Stock Market
- Equities
- RENB Stock
